In this sense, tauroursodeoxycholic acid (TUDCA), a hydrophilic biliary acid derivative, gained particular clinical interest for the treatment of ATTR amyloidosis since it has been previously referred to cause a decrease in the deposition of toxic pre-fibrillar TTR oligomers and to reduce the expression of several apoptotic and oxidative biomarkers associated with ATTR amyloid deposition in transgenic murine models treated with TUDCA (Macedo et al., 2008; Cardoso et al., 2010). Here, TTR is linked to amyloidosis.